The global Recombinant Hirudin market was valued at US$ 1600 million in 2023 and is anticipated to reach US$ 2327.5 million by 2030, witnessing a CAGR of 5.5% during the forecast period 2024-2030.

Recombinant Hirudin Market

Hirudin is the most potent natural inhibitor of thrombin. Unlike antithrombin, hirudin binds to and inhibits only the activity of thrombin, with a specific activity on fibrinogen. Therefore, hirudin prevents or dissolves the formation of clots and thrombi (i.e., it has a thrombolytic activity), and has therapeutic value in blood coagulation disorders, in the treatment of skin hematomas and of superficial varicose veins, either as an injectable or a topical application cream. In some aspects, hirudin has advantages over more commonly used anticoagulants and thrombolytics, such as heparin, as it does not interfere with the biological activity of other serum proteins, and can also act on complexed thrombin.

It is difficult to extract large amounts of hirudin from natural sources, so a method for producing and purifying this protein using recombinant biotechnology has been developed. This has led to the development and marketing of a number of hirudin-based anticoagulant pharmaceutical products. Several other direct thrombin inhibitors are derived chemically from hirudin.

Recombinant Hirudin is derived from yeast and the polypeptide chain contains 65 amino acids and its Mw is 6979.5 Dalton which is identical to natural Hirudin except for the substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. The Recombinant Hirudin is purified by proprietary chromatographic techniques.

The market drivers for Recombinant Hirudin are the increasing prevalence of thrombosis and tumor diseases, the growing demand for Recombinant Hirudin in the Asia Pacific and the Middle East & Africa regions, and the development of new products with improved features and performance.

The market constraints for Recombinant Hirudin are the high cost of Recombinant Hirudin compared to other anticoagulants, the limited availability and accessibility of Recombinant Hirudin in some regions, the need for regular monitoring and dosage adjustment of Recombinant Hirudin, and the risk of side effects and complications such as bleeding, allergic reactions, and antibody formation.

The market opportunities for Recombinant Hirudin are the increasing demand for Recombinant Hirudin among patients with heparin-induced thrombocytopenia (HIT), a condition where heparin causes low platelet count and increased risk of blood clots, the integration of Recombinant Hirudin with software and cloud-based platforms for better management and tracking of treatment outcomes, and the application of Recombinant Hirudin in new fields such as cosmetic surgery and dentistry.

This report aims to provide a comprehensive presentation of the global market for Recombinant Hirudin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Hirudin.

Report Scope

The Recombinant Hirudin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Hirudin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Recombinant Hirudin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Recombinant Hirudin Market Report

Report Metric	Details
Report Name	Recombinant Hirudin Market
Accounted market size in 2023	US$ 1600 million
Forecasted market size in 2030	US$ 2327.5 million
CAGR	5.5%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	12000ATU/mg 16000ATU/mg
Segment by Application	Thrombosis Disease Tumor Disease
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Abbott, The Medicines Company, Teva Pharmaceutical, Pfizer, Pentapharm, PrimeGene, Aniara Diagnostica, Bioassay Technology Laboratory, Novus Biologicals, Merck KGaA
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Hirudin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Hirudin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Recombinant Hirudin Market growing?

Ans: The Recombinant Hirudin Market witnessing a CAGR of 5.5% during the forecast period 2024-2030.

What is the Recombinant Hirudin Market size in 2030?

Ans: The Recombinant Hirudin Market size in 2030 will be US$ 2327.5 million.

Who are the main players in the Recombinant Hirudin Market report?

Ans: The main players in the Recombinant Hirudin Market are Abbott, The Medicines Company, Teva Pharmaceutical, Pfizer, Pentapharm, PrimeGene, Aniara Diagnostica, Bioassay Technology Laboratory, Novus Biologicals, Merck KGaA

What are the Application segmentation covered in the Recombinant Hirudin Market report?

Ans: The Applications covered in the Recombinant Hirudin Market report are Thrombosis Disease, Tumor Disease

What are the Type segmentation covered in the Recombinant Hirudin Market report?

Ans: The Types covered in the Recombinant Hirudin Market report are 12000ATU/mg, 16000ATU/mg

1 Recombinant Hirudin Market Overview

1.1 Product Overview and Scope of Recombinant Hirudin

1.2 Recombinant Hirudin Segment by Type

1.2.1 Global Recombinant Hirudin Market Value Comparison by Type (2024-2030)

1.2.2 12000ATU/mg

1.2.3 16000ATU/mg

1.3 Recombinant Hirudin Segment by Application

1.3.1 Global Recombinant Hirudin Market Value by Application: (2024-2030)

1.3.2 Thrombosis Disease

1.3.3 Tumor Disease

1.4 Global Recombinant Hirudin Market Size Estimates and Forecasts

1.4.1 Global Recombinant Hirudin Revenue 2019-2030

1.4.2 Global Recombinant Hirudin Sales 2019-2030

1.4.3 Global Recombinant Hirudin Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Recombinant Hirudin Market Competition by Manufacturers

2.1 Global Recombinant Hirudin Sales Market Share by Manufacturers (2019-2024)

2.2 Global Recombinant Hirudin Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Recombinant Hirudin Average Price by Manufacturers (2019-2024)

2.4 Global Recombinant Hirudin Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Recombinant Hirudin, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Recombinant Hirudin, Product Type & Application

2.7 Recombinant Hirudin Market Competitive Situation and Trends

2.7.1 Recombinant Hirudin Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Recombinant Hirudin Players Market Share by Revenue

2.7.3 Global Recombinant Hirudin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Recombinant Hirudin Retrospective Market Scenario by Region

3.1 Global Recombinant Hirudin Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Recombinant Hirudin Global Recombinant Hirudin Sales by Region: 2019-2030

3.2.1 Global Recombinant Hirudin Sales by Region: 2019-2024

3.2.2 Global Recombinant Hirudin Sales by Region: 2025-2030

3.3 Global Recombinant Hirudin Global Recombinant Hirudin Revenue by Region: 2019-2030

3.3.1 Global Recombinant Hirudin Revenue by Region: 2019-2024

3.3.2 Global Recombinant Hirudin Revenue by Region: 2025-2030

3.4 North America Recombinant Hirudin Market Facts & Figures by Country

3.4.1 North America Recombinant Hirudin Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Recombinant Hirudin Sales by Country (2019-2030)

3.4.3 North America Recombinant Hirudin Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Recombinant Hirudin Market Facts & Figures by Country

3.5.1 Europe Recombinant Hirudin Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Recombinant Hirudin Sales by Country (2019-2030)

3.5.3 Europe Recombinant Hirudin Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Recombinant Hirudin Market Facts & Figures by Country

3.6.1 Asia Pacific Recombinant Hirudin Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Recombinant Hirudin Sales by Country (2019-2030)

3.6.3 Asia Pacific Recombinant Hirudin Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Recombinant Hirudin Market Facts & Figures by Country

3.7.1 Latin America Recombinant Hirudin Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Recombinant Hirudin Sales by Country (2019-2030)

3.7.3 Latin America Recombinant Hirudin Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Recombinant Hirudin Market Facts & Figures by Country

3.8.1 Middle East and Africa Recombinant Hirudin Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Recombinant Hirudin Sales by Country (2019-2030)

3.8.3 Middle East and Africa Recombinant Hirudin Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Recombinant Hirudin Sales by Type (2019-2030)

4.1.1 Global Recombinant Hirudin Sales by Type (2019-2024)

4.1.2 Global Recombinant Hirudin Sales by Type (2025-2030)

4.1.3 Global Recombinant Hirudin Sales Market Share by Type (2019-2030)

4.2 Global Recombinant Hirudin Revenue by Type (2019-2030)

4.2.1 Global Recombinant Hirudin Revenue by Type (2019-2024)

4.2.2 Global Recombinant Hirudin Revenue by Type (2025-2030)

4.2.3 Global Recombinant Hirudin Revenue Market Share by Type (2019-2030)

4.3 Global Recombinant Hirudin Price by Type (2019-2030)

5 Segment by Application

5.1 Global Recombinant Hirudin Sales by Application (2019-2030)

5.1.1 Global Recombinant Hirudin Sales by Application (2019-2024)

5.1.2 Global Recombinant Hirudin Sales by Application (2025-2030)

5.1.3 Global Recombinant Hirudin Sales Market Share by Application (2019-2030)

5.2 Global Recombinant Hirudin Revenue by Application (2019-2030)

5.2.1 Global Recombinant Hirudin Revenue by Application (2019-2024)

5.2.2 Global Recombinant Hirudin Revenue by Application (2025-2030)

5.2.3 Global Recombinant Hirudin Revenue Market Share by Application (2019-2030)

5.3 Global Recombinant Hirudin Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Abbott

6.1.1 Abbott Corporation Information

6.1.2 Abbott Description and Business Overview

6.1.3 Abbott Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Abbott Recombinant Hirudin Product Portfolio

6.1.5 Abbott Recent Developments/Updates

6.2 The Medicines Company

6.2.1 The Medicines Company Corporation Information

6.2.2 The Medicines Company Description and Business Overview

6.2.3 The Medicines Company Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.2.4 The Medicines Company Recombinant Hirudin Product Portfolio

6.2.5 The Medicines Company Recent Developments/Updates

6.3 Teva Pharmaceutical

6.3.1 Teva Pharmaceutical Corporation Information

6.3.2 Teva Pharmaceutical Description and Business Overview

6.3.3 Teva Pharmaceutical Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Teva Pharmaceutical Recombinant Hirudin Product Portfolio

6.3.5 Teva Pharmaceutical Recent Developments/Updates

6.4 Pfizer

6.4.1 Pfizer Corporation Information

6.4.2 Pfizer Description and Business Overview

6.4.3 Pfizer Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Pfizer Recombinant Hirudin Product Portfolio

6.4.5 Pfizer Recent Developments/Updates

6.5 Pentapharm

6.5.1 Pentapharm Corporation Information

6.5.2 Pentapharm Description and Business Overview

6.5.3 Pentapharm Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Pentapharm Recombinant Hirudin Product Portfolio

6.5.5 Pentapharm Recent Developments/Updates

6.6 PrimeGene

6.6.1 PrimeGene Corporation Information

6.6.2 PrimeGene Description and Business Overview

6.6.3 PrimeGene Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.6.4 PrimeGene Recombinant Hirudin Product Portfolio

6.6.5 PrimeGene Recent Developments/Updates

6.7 Aniara Diagnostica

6.6.1 Aniara Diagnostica Corporation Information

6.6.2 Aniara Diagnostica Description and Business Overview

6.6.3 Aniara Diagnostica Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Aniara Diagnostica Recombinant Hirudin Product Portfolio

6.7.5 Aniara Diagnostica Recent Developments/Updates

6.8 Bioassay Technology Laboratory

6.8.1 Bioassay Technology Laboratory Corporation Information

6.8.2 Bioassay Technology Laboratory Description and Business Overview

6.8.3 Bioassay Technology Laboratory Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Bioassay Technology Laboratory Recombinant Hirudin Product Portfolio

6.8.5 Bioassay Technology Laboratory Recent Developments/Updates

6.9 Novus Biologicals

6.9.1 Novus Biologicals Corporation Information

6.9.2 Novus Biologicals Description and Business Overview

6.9.3 Novus Biologicals Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Novus Biologicals Recombinant Hirudin Product Portfolio

6.9.5 Novus Biologicals Recent Developments/Updates

6.10 Merck KGaA

6.10.1 Merck KGaA Corporation Information

6.10.2 Merck KGaA Description and Business Overview

6.10.3 Merck KGaA Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Merck KGaA Recombinant Hirudin Product Portfolio

6.10.5 Merck KGaA Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Recombinant Hirudin Industry Chain Analysis

7.2 Recombinant Hirudin Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Recombinant Hirudin Production Mode & Process

7.4 Recombinant Hirudin Sales and Marketing

7.4.1 Recombinant Hirudin Sales Channels

7.4.2 Recombinant Hirudin Distributors

7.5 Recombinant Hirudin Customers

8 Recombinant Hirudin Market Dynamics

8.1 Recombinant Hirudin Industry Trends

8.2 Recombinant Hirudin Market Drivers

8.3 Recombinant Hirudin Market Challenges

8.4 Recombinant Hirudin Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Abbott

The Medicines Company

Teva Pharmaceutical

Pfizer Inc

Pentapharm

Bioassay Technology Laboratory

List of Tables

Table 1. Global Recombinant Hirudin Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Recombinant Hirudin Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Recombinant Hirudin Market Competitive Situation by Manufacturers in 2023

Table 4. Global Recombinant Hirudin Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Recombinant Hirudin Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Recombinant Hirudin Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Recombinant Hirudin Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Recombinant Hirudin Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Recombinant Hirudin, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Recombinant Hirudin, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Recombinant Hirudin, Product Type & Application

Table 12. Global Key Manufacturers of Recombinant Hirudin, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Recombinant Hirudin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Hirudin as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Recombinant Hirudin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Recombinant Hirudin Sales by Region (2019-2024) & (K Units)

Table 18. Global Recombinant Hirudin Sales Market Share by Region (2019-2024)

Table 19. Global Recombinant Hirudin Sales by Region (2025-2030) & (K Units)

Table 20. Global Recombinant Hirudin Sales Market Share by Region (2025-2030)

Table 21. Global Recombinant Hirudin Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Recombinant Hirudin Revenue Market Share by Region (2019-2024)

Table 23. Global Recombinant Hirudin Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Recombinant Hirudin Revenue Market Share by Region (2025-2030)

Table 25. North America Recombinant Hirudin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Recombinant Hirudin Sales by Country (2019-2024) & (K Units)

Table 27. North America Recombinant Hirudin Sales by Country (2025-2030) & (K Units)

Table 28. North America Recombinant Hirudin Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Recombinant Hirudin Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Recombinant Hirudin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Recombinant Hirudin Sales by Country (2019-2024) & (K Units)

Table 32. Europe Recombinant Hirudin Sales by Country (2025-2030) & (K Units)

Table 33. Europe Recombinant Hirudin Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Recombinant Hirudin Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Recombinant Hirudin Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Recombinant Hirudin Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Recombinant Hirudin Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Recombinant Hirudin Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Recombinant Hirudin Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Recombinant Hirudin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Recombinant Hirudin Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Recombinant Hirudin Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Recombinant Hirudin Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Recombinant Hirudin Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Recombinant Hirudin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Recombinant Hirudin Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Recombinant Hirudin Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Recombinant Hirudin Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Recombinant Hirudin Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Recombinant Hirudin Sales (K Units) by Type (2019-2024)

Table 51. Global Recombinant Hirudin Sales (K Units) by Type (2025-2030)

Table 52. Global Recombinant Hirudin Sales Market Share by Type (2019-2024)

Table 53. Global Recombinant Hirudin Sales Market Share by Type (2025-2030)

Table 54. Global Recombinant Hirudin Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Recombinant Hirudin Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Recombinant Hirudin Revenue Market Share by Type (2019-2024)

Table 57. Global Recombinant Hirudin Revenue Market Share by Type (2025-2030)

Table 58. Global Recombinant Hirudin Price (US$/Unit) by Type (2019-2024)

Table 59. Global Recombinant Hirudin Price (US$/Unit) by Type (2025-2030)

Table 60. Global Recombinant Hirudin Sales (K Units) by Application (2019-2024)

Table 61. Global Recombinant Hirudin Sales (K Units) by Application (2025-2030)

Table 62. Global Recombinant Hirudin Sales Market Share by Application (2019-2024)

Table 63. Global Recombinant Hirudin Sales Market Share by Application (2025-2030)

Table 64. Global Recombinant Hirudin Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Recombinant Hirudin Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Recombinant Hirudin Revenue Market Share by Application (2019-2024)

Table 67. Global Recombinant Hirudin Revenue Market Share by Application (2025-2030)

Table 68. Global Recombinant Hirudin Price (US$/Unit) by Application (2019-2024)

Table 69. Global Recombinant Hirudin Price (US$/Unit) by Application (2025-2030)

Table 70. Abbott Corporation Information

Table 71. Abbott Description and Business Overview

Table 72. Abbott Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Abbott Recombinant Hirudin Product

Table 74. Abbott Recent Developments/Updates

Table 75. The Medicines Company Corporation Information

Table 76. The Medicines Company Description and Business Overview

Table 77. The Medicines Company Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. The Medicines Company Recombinant Hirudin Product

Table 79. The Medicines Company Recent Developments/Updates

Table 80. Teva Pharmaceutical Corporation Information

Table 81. Teva Pharmaceutical Description and Business Overview

Table 82. Teva Pharmaceutical Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Teva Pharmaceutical Recombinant Hirudin Product

Table 84. Teva Pharmaceutical Recent Developments/Updates

Table 85. Pfizer Corporation Information

Table 86. Pfizer Description and Business Overview

Table 87. Pfizer Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Pfizer Recombinant Hirudin Product

Table 89. Pfizer Recent Developments/Updates

Table 90. Pentapharm Corporation Information

Table 91. Pentapharm Description and Business Overview

Table 92. Pentapharm Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Pentapharm Recombinant Hirudin Product

Table 94. Pentapharm Recent Developments/Updates

Table 95. PrimeGene Corporation Information

Table 96. PrimeGene Description and Business Overview

Table 97. PrimeGene Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. PrimeGene Recombinant Hirudin Product

Table 99. PrimeGene Recent Developments/Updates

Table 100. Aniara Diagnostica Corporation Information

Table 101. Aniara Diagnostica Description and Business Overview

Table 102. Aniara Diagnostica Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Aniara Diagnostica Recombinant Hirudin Product

Table 104. Aniara Diagnostica Recent Developments/Updates

Table 105. Bioassay Technology Laboratory Corporation Information

Table 106. Bioassay Technology Laboratory Description and Business Overview

Table 107. Bioassay Technology Laboratory Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Bioassay Technology Laboratory Recombinant Hirudin Product

Table 109. Bioassay Technology Laboratory Recent Developments/Updates

Table 110. Novus Biologicals Corporation Information

Table 111. Novus Biologicals Description and Business Overview

Table 112. Novus Biologicals Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Novus Biologicals Recombinant Hirudin Product

Table 114. Novus Biologicals Recent Developments/Updates

Table 115. Merck KGaA Corporation Information

Table 116. Merck KGaA Description and Business Overview

Table 117. Merck KGaA Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Merck KGaA Recombinant Hirudin Product

Table 119. Merck KGaA Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Recombinant Hirudin Distributors List

Table 123. Recombinant Hirudin Customers List

Table 124. Recombinant Hirudin Market Trends

Table 125. Recombinant Hirudin Market Drivers

Table 126. Recombinant Hirudin Market Challenges

Table 127. Recombinant Hirudin Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Recombinant Hirudin

Figure 2. Global Recombinant Hirudin Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Recombinant Hirudin Market Share by Type in 2023 & 2030

Figure 4. 12000ATU/mg Product Picture

Figure 5. 16000ATU/mg Product Picture

Figure 6. Global Recombinant Hirudin Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Recombinant Hirudin Market Share by Application in 2023 & 2030

Figure 8. Thrombosis Disease

Figure 9. Tumor Disease

Figure 10. Global Recombinant Hirudin Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 11. Global Recombinant Hirudin Market Size (2019-2030) & (US$ Million)

Figure 12. Global Recombinant Hirudin Sales (2019-2030) & (K Units)

Figure 13. Global Recombinant Hirudin Average Price (US$/Unit) & (2019-2030)

Figure 14. Recombinant Hirudin Report Years Considered

Figure 15. Recombinant Hirudin Sales Share by Manufacturers in 2023

Figure 16. Global Recombinant Hirudin Revenue Share by Manufacturers in 2023

Figure 17. The Global 5 and 10 Largest Recombinant Hirudin Players: Market Share by Revenue in 2023

Figure 18. Recombinant Hirudin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 19. Global Recombinant Hirudin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 20. North America Recombinant Hirudin Sales Market Share by Country (2019-2030)

Figure 21. North America Recombinant Hirudin Revenue Market Share by Country (2019-2030)

Figure 22. United States Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 23. Canada Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Europe Recombinant Hirudin Sales Market Share by Country (2019-2030)

Figure 25. Europe Recombinant Hirudin Revenue Market Share by Country (2019-2030)

Figure 26. Germany Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. France Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. U.K. Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Italy Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Russia Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Asia Pacific Recombinant Hirudin Sales Market Share by Region (2019-2030)

Figure 32. Asia Pacific Recombinant Hirudin Revenue Market Share by Region (2019-2030)

Figure 33. China Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Japan Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. South Korea Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. India Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Australia Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. China Taiwan Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Latin America Recombinant Hirudin Sales Market Share by Country (2019-2030)

Figure 41. Latin America Recombinant Hirudin Revenue Market Share by Country (2019-2030)

Figure 42. Mexico Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Brazil Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Argentina Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Recombinant Hirudin Sales Market Share by Country (2019-2030)

Figure 46. Middle East & Africa Recombinant Hirudin Revenue Market Share by Country (2019-2030)

Figure 47. Turkey Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. UAE Recombinant Hirudin Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Global Sales Market Share of Recombinant Hirudin by Type (2019-2030)

Figure 51. Global Revenue Market Share of Recombinant Hirudin by Type (2019-2030)

Figure 52. Global Recombinant Hirudin Price (US$/Unit) by Type (2019-2030)

Figure 53. Global Sales Market Share of Recombinant Hirudin by Application (2019-2030)

Figure 54. Global Revenue Market Share of Recombinant Hirudin by Application (2019-2030)

Figure 55. Global Recombinant Hirudin Price (US$/Unit) by Application (2019-2030)

Figure 56. Recombinant Hirudin Value Chain

Figure 57. Recombinant Hirudin Production Process

Figure 58. Channels of Distribution (Direct Vs Distribution)

Figure 59. Distributors Profiles

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions